Fundraising Fox

Axovia Therapeutics

6 employees on LinkedIn · 2 known investors

Axovia Therapeutics develops gene therapies for ciliopathies, with a lead program using an adeno-associated virus (AAV9) to deliver a functional copy of the BBS1 gene in patients with Bardet-Biedl Syndrome. The company aims to treat genetic forms of obesity and blindness associated with these disorders.

BiotechHealthtech

Founders & leadership

PBPhil Beales
Phil BealesCo-founder
VHVictor Hernandez
Victor HernandezCo-founder

Investors · 2

AlbionVCLondon
ALSA VenturesLondon

In the news

A Race Against Blindness has awarded to Axovia Therapeutics a further $1.1 million in grant funding to support the BBS1 clinical study - Axovia Therapeuticsaxoviatherapeutics.com · Jan 2026A Race Against Blindness Announces a Further $1 Million Grant to Support Sight-Saving Clinical Trial - Axovia Therapeuticsaxoviatherapeutics.com · Sep 2025

Frequently asked questions

What does Axovia Therapeutics do?
Axovia Therapeutics develops gene therapies for ciliopathies, with a lead program using an adeno-associated virus (AAV9) to deliver a functional copy of the BBS1 gene in patients with Bardet-Biedl Syndrome. The company aims to treat genetic forms of obesity and blindness associated with these disorders.
Who founded Axovia Therapeutics?
Axovia Therapeutics was founded by Phil Beales, Victor Hernandez.
Who are Axovia Therapeutics's investors?
Axovia Therapeutics's investors include AlbionVC, ALSA Ventures.